Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression
Ha-Young Park, In-Jae Oh, Bo Gun Kho, Tae-Ok Kim, Hong-Joon Shin, Cheol Kyu Park, Yong-Soo Kwon, Yu-Il Kim, Sung-Chul Lim, Young-Chul Kim, Yoo-Duk Choi
Tuberc Respir Dis. 2019;82(3):227-233.   Published online 2019 Feb 28     DOI:
Citations to this article as recorded by Crossref logo
Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors
Da Hyun Kang, Chaeuk Chung, Pureum Sun, Da Hye Lee, Song-I Lee, Dongil Park, Jeong Suk Koh, Yoonjoo Kim, Hyon-Seung Yi, Jeong Eun Lee
Cancer Immunology, Immunotherapy.2022; 71(3): 579.     CrossRef
Recent advances in diagnostic technologies in lung cancer
Hye Jung Park, Sang Hoon Lee, Yoon Soo Chang
The Korean Journal of Internal Medicine.2020; 35(2): 257.     CrossRef
Baseline Serum Interleukin-6 Levels Predict the Response of Patients with Advanced Non-small Cell Lung Cancer to PD-1/PD-L1 Inhibitors
Da Hyun Kang, Cheol-Kyu Park, Chaeuk Chung, In-Jae Oh, Young-Chul Kim, Dongil Park, Jinhyun Kim, Gye Cheol Kwon, Insun Kwon, Pureum Sun, Eui-Cheol Shin, Jeong Eun Lee
Immune Network.2020;[Epub]     CrossRef
Association with PD-L1 Expression and Clinicopathological Features in 1000 Lung Cancers: A Large Single-Institution Study of Surgically Resected Lung Cancers with a High Prevalence of EGFR Mutation
Lee, Kim, Sung, Lee, Han, Kim, Choi
International Journal of Molecular Sciences.2019; 20(19): 4794.     CrossRef